Therefore, it is essential to consider: (1) the inclusion of neuroinflammation in the current ‘amyloid-tau-neurodegeneration’ framework and (2) targeting neuroinflammation in the symptomatic stage of Alzheimer’s disease to preserve brain networks and delay disease progression. This evidence concerns the gene MAPT and Alzheimer disease.